Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 69 years, of any gender
- People diagnosed with Peripheral T-cell lymphoma (a type of blood cancer) according to specific 2016 medical guidelines, whose disease either came back after initially responding to standard chemotherapy (including after a stem cell transplant), did not respond well enough to standard chemotherapy, or who are not suitable for or have chosen not to have their own stem cells transplanted back into them — excluding a specific subtype called ALK+ anaplastic large cell lymphoma
- People who have a suitable stem cell donor available — either a related donor who matches at least 5 out of 10 key tissue markers, or an unrelated donor who matches at least 8 out of 10 key tissue markers
- People with a low score (2 or less) on a medical scale that measures health risks before a stem cell transplant (confirm with trial site)
- People who are reasonably active and able to care for themselves, rated 0–2 on a standard medical fitness scale
- People whose heart, lungs, liver, and kidneys are functioning well enough to meet specific test thresholds (confirm with trial site for exact values)
- People who are willing and able to understand the study and sign a consent form
Who may not be able to join:
- People with Peripheral T-cell lymphoma that does not meet the specific definitions of relapsed or treatment-resistant disease
- People who are unwilling to have a donor stem cell transplant
- People who have had a different cancer (other than certain blood cancers) within the past 5 years, unless it was certain well-treated skin cancers, early-stage cervical cancer, or a fully treated localised prostate cancer
- People who score 3 or higher on the standard medical fitness scale mentioned above
- People who score 3 or higher on the transplant health-risk scale mentioned above
- People with serious unstable health conditions, such as unstable chest pain, a stroke or mini-stroke in the past 3 months, a heart attack in the past 3 months, significant heart failure, serious heart rhythm problems, or serious liver, kidney, or lung blood pressure problems
- People with an active, uncontrolled infection
- People living with HIV
- People with active hepatitis B or hepatitis C that requires antiviral treatment
- People with a history of autoimmune disease (conditions where the immune system attacks the body)
- People who are pregnant or breastfeeding
- People who are able to have children but are unwilling to use contraception during treatment and for 12 months afterwards
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xianmin Song, MD, Shanghai General HospitalShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phone: +86 1350167250
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
1y and 2y-progression-free survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.